Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Cancer Invest. 2010 Nov;28(9):963-8. doi: 10.3109/07357907.2010.496759.

    Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US.

    Source

    Surveillance Research Program, National Cancer Institute, Bethesda, Maryland, USA. cronink@mail.nih.gov

    Abstract

    The goal of this study was to estimate prevalence of HER-2 positive tumors in a population-based sample of 1026 women diagnosed in 2005 with early stage breast cancer. We modeled the relationship between patient and tumor characteristics and HER-2. HER-2 positive estimates were 19% for women aged ≤ 49 years and 15% aged ≥ 50 years. HER-2 varied by tumor grade and size in women aged ≤ 49 years but was not significant in multivariate analysis. Tumor grade and race were associated with HER-2 for women aged ≥ 50 years after controlling for other variables. HER-2 varies by age and by race and tumor in older women.

    PMID:
    20690807
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Informa Healthcare

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk